A series of O-and N-prenyl secondary metabolites of insect, fungal, and plant origin have been evaluated for their topical anti-inflammatory activity using the Croton oil ear test in mice as a model of acute inflammation. Some of the tested compounds revealed an effect (ID 50 = 0.31 0.56 µmol/cm 2 ) comparable with that of the reference non-steroidal anti-inflammatory drug indomethacin (ID 50 = 0.23 mol/cm 2 ).
Oxyprenylated and azoprenylated compounds, such as isopentenyl-(C5), geranyl-(C10), and farnesyl-(C15) derivatives, represent a class of secondary metabolites that have been recognized in the last two decades as interesting and valuable biologically-active phytochemicals. Some representative prenyloxyphenyl-propanoids have shown valuable anti-inflammatory properties [1] . Since inflammation is a universal and physiological response involved in different pathological conditions, the evaluation of antiinflammatory properties of oxy-and azoprenylated secondary metabolites is a field of growing interest. Thus, we have evaluated the topical anti-inflammatory activity of 12 selected compounds (1-12) by the Croton oil ear test in mice [2] . The anti-inflammatory activity of compounds 1-12, administered at a dose of 0.3 mol/cm 2 , are reported in Table 1 , in comparison to that of the same dose of the non-steroidal anti-inflammatory drug indomethacin, used as a reference. Compounds 1, 2, 4, 5 and 7-11 induced significant reductions of edema, ranging from 14 to 52%, while compounds 3, 6 and 12 were inactive. Among the active compounds, 4, 8 and 11 exhibited only a weak anti-inflammatory effect, with edema reductions lower than 20%, whereas 2, 5, 7, and 9 provoked about 30% reduction. The highest activity (about 50% edema reduction) was observed for the aminoacid derivatives N-acetyl-O-isopentenyl-L-tyrosine (1) and N-isopentenylanthranilic acid geranyl ester (100. The equimolar dose of indomethacin induced a slightly higher effect (61% edema reduction).
The most active compounds (1 and 10), as well as compounds inducing about 30% edema reduction (2, 5, 7 and 9), were then further investigated for their dose-activity relationship, in comparison with indomethacin. The obtained results are summarized in Table 2 . At doses ranging from 0.1 to 1.0 mol/cm 2 , all the selected compounds exerted a dose-dependent anti-inflammatory activity, with edema inhibition reaching about 70% (compound 9) or 80 % (compounds 1, 2, 5, 7, 10) at the highest administered dose (1.0 mol/cm 2 ), comparable with that induced by indomethacin at the same dose (82% reduction). The anti-inflammatory potency of these compounds was evaluated by the dose inducing 50% edema inhibition (ID 50 ). The nitrogen-containing secondary metabolites 1 and 10 (ID 50 = 0.31 and 0.36 mol/cm 2 , respectively) were the most active, with an NPC Natural Product Communications 2014 Vol. 9 No. 1 85 -86 86 Natural Product Communications Vol. 9 (1) 2014 Epifano et al. inflammatory potency comparable with that of indomethacin (ID 50 = 0.26 mol/cm 2 ). Anyway, the anti-inflammatory potency of the other compounds (ID 50 = 0.44-0.56 mol/cm 2 ) was only two or less times lower than that of indomethacin. The results obtained herein represent in part a parallelism with already reported data indicating how tyrosine and N-substituted anthranilic acid derivatives act as effective anti-inflammatory agents [4] .
In conclusion, the findings described herein indicate that some oxyand azoprenylated naturally-occurring secondary metabolites could be regarded as potential novel and effective anti-inflammatory agents, with a potency comparable with that of the NSAID indomethacin. Two of these derivatives showed a high topical antiinflammatory activity in the Croton oil-induced ear dermatitis test in mice. For these reasons, the results of the present study could be considered as a topic for future studies aimed at better defining the pharmacological profile of these and other oxy-and azoprenylated secondary metabolites, and to develop a novel series of lead compounds.
Experimental
Compounds: The synthesis of compounds (1-12), was accomplished according to the procedures described previously [3] . All products were obtained in a high degree of purity (> 97%) estimated by GC-MS. were sacrificed and a plug (6 mm ) was excised from both the treated and untreated ears to quantify edema as weight difference between the two plugs. The anti-inflammatory activity was expressed as % edema reduction in mice treated with the compounds under test with regard to control mice. Edema values, expressed as means ± standard error (S.E.) of the mean, were analysed by one way analysis of variance followed by Dunnett's test for multiple comparison of unpaired data. A probability level lower than 0.05 was considered as significant.
